kidney stones and glp-1 Can GLP‑1 medications increase stone risk? A UAB urologist offers insight Do GLP-1 drugs have health

Biol Trace Elem Res (2023) 201(5):251223

Administration of the Gln synthetase inhibitor CB-839 promotes the differentiation and cytokine secretion of CD4 + Th 1 cells as well as CD8 + T cells while inhibiting the differentiation and co-function of Th 17 cells

Lixisenatide in Patients With Type 2 Diabetes and Acute Coronary Syndrome

Fluorescence measurements and assay to monitor the recovery after oxidative shock Fluorescence measurements were performed with a spectrofluorometer FP6500 (Jasco) at 30C with constant stirring

Retatrutide is a novel triple receptor agonist peptide that targets the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R)